Addition of tiagabine to second-generation antipsychotics in the treatment of recent-onset schizophrenia by modification of developmental reorganization of the prefrontal cortex.

Trial Profile

Addition of tiagabine to second-generation antipsychotics in the treatment of recent-onset schizophrenia by modification of developmental reorganization of the prefrontal cortex.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Tiagabine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 1 Jul 2012 to 1 Jul 2019.
    • 02 Mar 2017 Planned primary completion date changed from 1 Jul 2012 to 1 Jul 2018.
    • 28 Jul 2011 Planned end date (Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top